Hepatitis C genotype 4R resistance-associated polymorphisms: The achilles heel of the nonstructural 5A inhibitors?

Hepatology

Volumn 64, Issue 2, 2016, Pages 697-698

  Halfon, Philippe ^a,b   Mohamed, Sofiane ^b   Penaranda, Guillaume ^b   Khiri, Hacène ^b   Chiche, Laurent ^a   Nicolas, Carine ^c   Abergel, Armand ^c  

^a Européen Hospital   (France)

^b Laboratoire Alphabio   (France)

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; LEDIPASVIR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; SOFOSBUVIR;

AMINO ACID SEQUENCE; ANTIVIRAL THERAPY; DRUG TREATMENT FAILURE; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; SEQUENCE ALIGNMENT; TREATMENT RESPONSE;

EID: 84978998701     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28611     Document Type: Letter

References (4)

1. Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology 2015;62:1623-1632.
2. Abergel A, Loustaud-Ratti V, Metivier S, Jiang D, Kersey K, Knox SJ, et al. Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection. J Hepatol 2015;62(Suppl 2):S219-S220.
3. Zhou N, Hernandez D, Ueland J, Yang X, Yu F, Sims K, et al. NS5A sequence heterogeneity and mechanisms of daclatasvir resistance in hepatitis C virus genotype 4 infection. J infect Dis 2016;213:206-215.
4. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011;55:192-206.